Genexine (Korea) Performance
| 095700 Stock | KRW 5,840 210.00 3.47% |
The company retains a Market Volatility (i.e., Beta) of -0.36, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Genexine are expected to decrease at a much lower rate. During the bear market, Genexine is likely to outperform the market. At this point, Genexine has a negative expected return of -0.093%. Please make sure to check out Genexine's coefficient of variation, jensen alpha, treynor ratio, as well as the relationship between the standard deviation and total risk alpha , to decide if Genexine performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Genexine has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Genexine is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | -7.7 B |
Genexine |
Genexine Relative Risk vs. Return Landscape
If you would invest 682,000 in Genexine on August 31, 2024 and sell it today you would lose (77,000) from holding Genexine or give up 11.29% of portfolio value over 90 days. Genexine is generating negative expected returns and assumes 5.0805% volatility on return distribution over the 90 days horizon. Simply put, 45% of stocks are less volatile than Genexine, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Genexine Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genexine's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genexine, and traders can use it to determine the average amount a Genexine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0183
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 095700 |
Estimated Market Risk
| 5.08 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Genexine is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genexine by adding Genexine to a well-diversified portfolio.
Genexine Fundamentals Growth
Genexine Stock prices reflect investors' perceptions of the future prospects and financial health of Genexine, and Genexine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genexine Stock performance.
| Return On Equity | -10.06 | |||
| Return On Asset | -0.0172 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | (0.41) % | |||
| Current Valuation | 2.14 T | |||
| Shares Outstanding | 20.55 M | |||
| Price To Sales | 10.84 X | |||
| Revenue | 36.83 B | |||
| EBITDA | (14.76 B) | |||
| Cash And Equivalents | 27.8 B | |||
| Cash Per Share | 687.14 X | |||
| Total Debt | 40.79 B | |||
| Debt To Equity | 31.90 % | |||
| Book Value Per Share | 3,270 X | |||
| Cash Flow From Operations | (12.75 B) | |||
| Earnings Per Share | (1,283) X | |||
| Total Asset | 636.86 B | |||
| Retained Earnings | (28.44 B) | |||
| Current Asset | 11.66 B | |||
| Current Liabilities | 5.16 B | |||
About Genexine Performance
By analyzing Genexine's fundamental ratios, stakeholders can gain valuable insights into Genexine's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genexine has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genexine has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea. Genexine is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about Genexine performance evaluation
Checking the ongoing alerts about Genexine for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genexine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genexine generated a negative expected return over the last 90 days | |
| Genexine has high historical volatility and very poor performance | |
| The company reported the revenue of 36.83 B. Net Loss for the year was (48.56 B) with profit before overhead, payroll, taxes, and interest of 9.76 B. | |
| Genexine has accumulated about 27.8 B in cash with (12.75 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 687.14. | |
| Roughly 21.0% of the company shares are owned by insiders or employees |
- Analyzing Genexine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genexine's stock is overvalued or undervalued compared to its peers.
- Examining Genexine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genexine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genexine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genexine's stock. These opinions can provide insight into Genexine's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genexine Stock analysis
When running Genexine's price analysis, check to measure Genexine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genexine is operating at the current time. Most of Genexine's value examination focuses on studying past and present price action to predict the probability of Genexine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genexine's price. Additionally, you may evaluate how the addition of Genexine to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |